Status:
RECRUITING
The Real-world Treatment Satisfaction by Gefapixiant in RCC
Lead Sponsor:
Nagoya City University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Chronic Cough
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cou...
Detailed Description
Chronic cough has a high global prevalence, but appears to be poorly recognized. Most patients respond to specific treatments against causes of chronic cough. Meanwhile, cough is refractory to such tr...
Eligibility Criteria
Inclusion
- Adult patients with RCC and UCC (8 weeks or more).
- Cough is refractory to intensive specific treatments for causes of chronic cough.
- Never smokers and ex-smokers with having smoking history of ≤20 pack-years.
Exclusion
- Patients with lung cancer, interstitial lung diseases, bronchiectasis, or respiratory infection such as tuberculosis and acute pneumonia.
- Current smoker, ex-smokers with having smoking history of \>20 pack-years, or those who quit smoking within six months prior to receiving gefapixant.
- Those who are pregnant.
Key Trial Info
Start Date :
December 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT06542484
Start Date
December 4 2024
End Date
June 30 2026
Last Update
January 29 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nagoya City University
Nagoya, Aichi-ken, Japan, 467-8601
2
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan, 4678601